Eureka Technologies Receives FDA’s OK to Move T-cell Therapy into Clinical Trials
News
The U.S. Food and Drug Administration (FDA) has approved the T-cell therapy ET190L1-ARTEMIS to move into clinical trials for the treatment of relapsed and refractory CD19-positive non-Hodgkin’s lymphoma (NHL). Following the ... Read more